{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-105533","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.286068+00:00","generated_at":"2026-05-30T21:04:09.006618+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Novavax clarifies it has not updated FY2024 guidance after analyst report","bullets":["Analyst report published Oct 1, 2024 cited management discussions on US COVID-19 vaccine market.","Novavax has not updated or reaffirmed its full year 2024 guidance issued August 8, 2024.","Company expects US COVID-19 vaccination market for 2024-2025 season to be similar to last year.","No change to previously issued FY2024 guidance; no new financial information provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-105533","json":"https://secwatch.observer/filing/0001104659-24-105533.json","markdown":"https://secwatch.observer/filing/0001104659-24-105533.md","text":"https://secwatch.observer/filing/0001104659-24-105533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924105533/0001104659-24-105533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924105533/tm2425496d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:04:09.006618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}